# BEAM — local-model

## Metadata

ticker: BEAM
arm: local-model
judge_prompt_version: v2
context_sha256: 3a090720a067b4b5e66debc6ce0536d7f419a1fa2f38e287660c136f37e77ce4
local_model_served_name: financial-lora-w4a16
local_model_dir: qwen-ft-w4a16
local_model_backend: openai
local_model_url: http://vllm.financial-agent.svc:8000
local_model_sampling: {"max_tokens": 512, "min_p": 0.0, "repetition_penalty": 1.1, "temperature": 0.1, "top_k": 20, "top_p": 0.8}

## Retrieved source context

STOCK DATA:
{
  "ticker": "BEAM",
  "company_name": "Beam Therapeutics Inc.",
  "current_price": 24.23,
  "currency": "USD",
  "market_cap": 2502660096.0,
  "forward_pe": -5.110337,
  "week_52_high": 38.26,
  "week_52_low": 20.23,
  "revenue": 156035008.0,
  "net_income": -86520000.0,
  "profit_margin": -0.55449003,
  "sector": "Healthcare",
  "industry": "Biotechnology"
}

NEWS ARTICLES:
[
  {
    "title": null,
    "source": null,
    "published_at": null,
    "description": null
  }
]

SEC FILING SUMMARIES:
{
  "10-K": {
    "form_type": "10-K",
    "filing_date": "2026-02-24",
    "summary": "Item 1A. Risk Factors. You should carefully consider the risks and uncertainties described below together with all of the other information contained in this Annual Report on Form 10-K, including our consolidated financial statements and related notes appearing at the end of this Annual Report on Form 10-K, in evaluating our company. If any of the events or developments described below were to occur, our business, prospects, operating results and financial condition could suffer materially, and the trading price of our common stock could decline. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently believe to be immaterial may also adversely affect our business. Risks related to our fina"
  },
  "10-Q": {
    "form_type": "10-Q",
    "filing_date": "2026-08-04",
    "summary": "Item 1A. Risk Fa ctors. In addition to the other information set forth in this Quarterly Report on Form 10-Q, you should carefully consider the factors discussed in the sections titled sections titled \u201cRisk Factors Summary\u201d and \u201cItem 1A. Risk Factors\u201d in the 2025 Form 10-K, which could materially affect our business, financial condition or future results. The risk factors disclosure in the 2025 Form 10-K is qualified by the information in this Quarterly Report on Form 10-Q. The risks described in the 2025 Form 10\u2013K are not our only risks. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition or future results. The risk factors set forth below represent new risk factors o"
  }
}

RAG — SEC HIGHLIGHTS:
[From Pinecone cache] # Key Takeaways from the Latest SEC Filings

## Financial Position and Losses

The company has incurred substantial operating losses since inception, with net losses of $80.0 million, $376.7 million, and $132.5 million for the years ended December 31, 2025, 2024, and 2023, respectively. An accumulated deficit of $1.6 billion has been recorded as of December 31, 2025. The company expects to continue incurring significant losses for the foreseeable future and may never achieve profitability.

## Capital Requirements and Funding

As of December 31, 2025, the company had $1.2 billion in cash, cash equivalents, and marketable securities, which management believes will fund operations and capital expenditures for at least the next 12 months. However, the company will require substantial additional funding to support:

- Continued research and development activities
- Expansion of clinical trials
- Pursuit of marketing approvals
- Commercialization infrastructure development
- Manufacturing facility operations

The company has no committed source of additional capital beyond its credit facility with Sixth Street Lending Partners.

## Development Stage and Risks

As an early-stage company founded in January 2017, it has not completed any pivotal clinical trials or obtained marketing approvals for any product candidates. The company has previously delayed, reduced, or eliminated certain research programs to manage expenses, and may do so again if unable to raise capital on acceptable terms.

## Strategic Challenges

Raising additional capital through equity or debt could dilute shareholder ownership and impose operational restrictions. Alternatively, securing funding through collaborations or licensing arrangements may require relinquishing valuable rights to technologies or product candidates.

RAG — RISK FACTORS:
[From Pinecone cache] # Primary Risk Factors Disclosed

The company discloses several significant risk factors, with the primary ones being:

## Financial Position and Capital Needs
- **Substantial accumulated losses**: The company has an accumulated deficit of $1.6 billion as of December 31, 2025, with net losses of $80.0 million, $376.7 million, and $132.5 million for 2025, 2024, and 2023, respectively.
- **Expectation of continued losses**: The company expects to incur losses for the foreseeable future and may never achieve profitability.
- **Need for additional funding**: Substantial additional capital will be required to fund ongoing operations, clinical trials, and potential commercialization efforts. Without adequate funding, the company may be forced to delay, reduce, or eliminate research and development programs.

## Product Development and Commercialization Challenges
- **No completed pivotal trials**: The company has not completed any pivotal clinical trials and has no approved product candidates for commercialization.
- **Long development timelines**: Developing new medicines typically takes 10 to 15 years from discovery to patient availability.
- **Limited operating history**: As an early-stage company in a rapidly evolving field, the company has limited experience in successfully completing clinical trials, obtaining marketing approvals, manufacturing at commercial scale, or conducting commercialization activities.
- **Uncertain success**: There is no guarantee that identified product candidates will generate significant revenues or achieve commercial success, even if approved.

## Operational Uncertainties
- **Unpredictable expenses and challenges**: As a new business transitioning from research to commercialization, the company may encounter unforeseen expenses, difficulties, and complications.

## Pre-written sections (judge input)

### Financial Health

Beam Therapeutics Inc., a biotechnology company focused on developing innovative therapies for patients with rare diseases and cancer. As of December 31, 2025, the company reported $15.6 billion in annual revenue and $8.6 billion in net income. The company's net loss per share was $0.55 as of December 31, 2025.

### Recent Developments

Limited current news is available for analysis. Beam Therapeutics' most recent SEC filings—a 10-K filed in February 2026 and a 10-Q filed in August 2026—emphasize significant risk factors related to the company's financial condition and operations, suggesting ongoing challenges in its business execution. With a negative profit margin of -55.4% and net losses of $86.5 million against $156 million in revenue, the company remains unprofitable and cash-consumptive, typical for early-stage biotech firms. Investors should monitor upcoming clinical trial results and regulatory milestones, as these will be critical catalysts for validating Beam's base editing platform and justifying its current $2.5 billion market valuation.

### SEC Filing Highlights

Beam Therapeutics reported net losses of $80.0 million in 2025 and has accumulated a $1.6 billion deficit since inception, with expectations to continue incurring significant losses as an early-stage company. The company maintains $1.2 billion in cash and equivalents as of December 31, 2025, sufficient to fund operations for at least the next 12 months, but will require substantial additional capital to advance clinical trials and pursue commercialization. As a development-stage company founded in 2017, Beam has not completed pivotal clinical trials or obtained marketing approvals for any product candidates, and faces strategic challenges in securing future funding without diluting shareholder ownership or relinquishing valuable technology rights.

### Primary Risk Factors Disclosed

The company discloses several significant risk factors, including:

#### Financial Position and Capital Needs
- The company has an accumulated deficit of $1.6 billion as of December 31, 2025, with net losses of $80.0 million, $376.7 million, and $132.5 million for 2025, 2024, and 2023, respectively.
- The company expects to incur losses for the foreseeable future and may never achieve profitability.
- The company requires substantial additional capital to fund its ongoing operations, clinical trials, and potential commercialization efforts. Without adequate funding, the company may be forced to delay, reduce, or eliminate research and development programs.

#### Product Development and Commercialization Challenges
- The company has not completed any pivotal clinical trials and has no approved product candidates for commercialization.
- The development process for new medicines typically takes 10 to 15 years from discovery to patient availability.
- The company faces uncertainties related to the successful completion of clinical trials, obtaining marketing approvals, manufacturing at commercial scale, and conducting commercialization activities.

## Audited (Exec Summary + Outlook)

### Executive Summary
Beam Therapeutics is an early-stage biotechnology company developing base editing therapies for rare diseases and cancer, operating with a $2.5 billion market valuation and $1.2 billion in cash and equivalents as of December 31, 2025, against an accumulated deficit of $1.6 billion since its 2017 founding. The stock is notable now as a high-risk, high-optionality bet on a novel gene-editing platform that has yet to produce an approved product, leaving valuation almost entirely dependent on clinical and regulatory progress rather than commercial fundamentals. The single most important near-term variable is the outcome of upcoming clinical trial results, which will either validate Beam's base editing platform as a credible therapeutic modality or materially erode confidence in the company's core scientific thesis.

### Outlook
The directional outlook for Beam Therapeutics is **cautious**, though not without potential upside for investors with high risk tolerance and a long time horizon. The primary tailwind is the scientific novelty of base editing as a precision genetic medicine approach, which, if validated clinically, could differentiate Beam meaningfully from broader gene-editing competitors. The $1.2 billion cash runway provides near-term operational stability and reduces immediate dilution pressure, offering a window for clinical data to mature. However, headwinds are substantial: the company carries a $1.6 billion accumulated deficit, has no approved products, and faces a development timeline that typically spans ten to fifteen years from discovery to patient availability, meaning commercial inflection remains distant. Key variables to monitor include the safety and efficacy readouts from ongoing clinical trials, the pace and terms of any future capital raises or partnership agreements, and the regulatory posture of health authorities toward novel gene-editing modalities. The thesis would strengthen meaningfully on positive clinical data demonstrating durable efficacy and an acceptable safety profile, or on a strategic partnership that validates the platform without excessive dilution of shareholder value. Conversely, clinical setbacks, adverse safety signals, or a deteriorating capital-raising environment would weaken the investment case considerably and could force difficult decisions around program prioritization.

---
*This brief is for informational purposes only and does not constitute financial advice.*

## Judge findings

I will now audit every specific quantitative figure, price target, threshold, ratio, metric, percentage, named product milestone, or forward-looking number in the **Executive Summary** and **Outlook** sections.

---

**EXECUTIVE SUMMARY**

---

CLAIM: "$2.5 billion market valuation"
LABEL: SUPPORTED
REASON: The raw source data lists market_cap as $2,502,660,096, which rounds to $2.5 billion; this figure also appears in the pre-written "Recent Developments" section.

---

CLAIM: "$1.2 billion in cash and equivalents as of December 31, 2025"
LABEL: SUPPORTED
REASON: The RAG — SEC Highlights and SEC Filing Highlights pre-written section both explicitly state "the company had $1.2 billion in cash, cash equivalents, and marketable securities" as of December 31, 2025.

---

CLAIM: "accumulated deficit of $1.6 billion since its 2017 founding"
LABEL: SUPPORTED
REASON: Both the RAG — SEC Highlights and RAG — Risk Factors explicitly state an accumulated deficit of $1.6 billion as of December 31, 2025, and the SEC Highlights note the company was "founded in January 2017."

---

CLAIM: "has yet to produce an approved product"
LABEL: SUPPORTED
REASON: The RAG — SEC Highlights and Risk Factors both explicitly state the company "has not completed any pivotal clinical trials or obtained marketing approvals for any product candidates."

---

**OUTLOOK**

---

CLAIM: "$1.2 billion cash runway"
LABEL: SUPPORTED
REASON: Explicitly stated in the RAG — SEC Highlights: "the company had $1.2 billion in cash, cash equivalents, and marketable securities" as of December 31, 2025.

---

CLAIM: "$1.6 billion accumulated deficit"
LABEL: SUPPORTED
REASON: Explicitly stated in both the RAG — SEC Highlights and RAG — Risk Factors sections as of December 31, 2025.

---

CLAIM: "no approved products"
LABEL: SUPPORTED
REASON: The RAG — SEC Highlights and Risk Factors both explicitly confirm the company has no approved product candidates.

---

CLAIM: "development timeline that typically spans ten to fifteen years from discovery to patient availability"
LABEL: SUPPORTED
REASON: The RAG — Risk Factors and the pre-written "Primary Risk Factors Disclosed" section both explicitly state "developing new medicines typically takes 10 to 15 years from discovery to patient availability."

---

**No other specific quantitative figures, price targets, thresholds, ratios, metrics, percentages, named product milestones, or forward-looking numbers appear in the Executive Summary or Outlook sections.** All remaining language is qualitative or directional and does not constitute a verifiable quantitative or factual claim subject to this audit framework.
